EGFR and neoplasm: Epidermal growth factor receptor (EGFR) inhibitors, (such as Cetuximab, Panitumumab, Erlotinib, and Gefitinib), work by focusing on and obstructing the signaling pathway and signal transduction that promote tumor growth.